Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0
作者：
Franchini, Massimo [1 ]
机构：
[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;
D O I：
10.2450/2010.0067.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 296
页数：5
相关论文
共 48 条
[21]   The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile [J].
Greninger, D. A. ;
Saint-Remy, J. M. ;
Jacquemin, M. ;
Benhida, A. ;
Dimichele, D. M. .
HAEMOPHILIA, 2008, 14 (02) :295-302
[22]   Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response [J].
Gringeri, A. ;
Musso, R. ;
Mazzucconi, M. G. ;
Piseddu, G. ;
Schiavoni, M. ;
Pignoloni, P. ;
Mannucci, P. M. .
HAEMOPHILIA, 2007, 13 (04) :373-379
[23]   Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group [J].
Gringeri, A ;
Mantovani, LG ;
Scalone, L ;
Mannucci, PM .
BLOOD, 2003, 102 (07) :2358-2363
[24]   The epidemiology of factor VIII inhibitors [J].
Hay, Charles R. M. .
HAEMOPHILIA, 2006, 12 :23-28
[25]  
Iotto A, 2010, J THROMB HAEMOST
[26]   Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B. A prospective multi-center study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH) [J].
Kreuz, W ;
Auerswald, G ;
Budde, U ;
Klose, HJ ;
Lenk, H .
35TH HEMOPHILIA SYMPOSIUM, 2006, :34-+
[27]   Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A - Results of an international clinical investigation [J].
Kreuz, W ;
Gill, JC ;
Rothschild, C ;
Manco-Johnson, MJ ;
Lusher, JM ;
Kellermann, E ;
Gorina, E ;
Larson, PJ .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (03) :457-467
[28]   Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products [J].
Kreuz, W ;
Ettingshausen, CE ;
Zyschka, A ;
Oldenburg, J ;
Saguer, IM ;
Ehrenforth, S ;
Klingebiel, T .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03) :285-290
[29]   Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors [J].
Kurth, M. A. H. ;
Dimichele, D. ;
Sexauer, C. ;
Sanders, J. M. ;
Torres, M. ;
Zappa, S. C. ;
Ragni, M. ;
Leonard, N. .
HAEMOPHILIA, 2008, 14 (01) :50-55
[30]   Prophylaxis in haemophilia patients with inhibitors [J].
Leissinger, C. A. .
HAEMOPHILIA, 2006, 12 :67-72
12345